Comparative symptomatological and evoked potential studies with d-amphetamine, thioridazine, and placebo in hyperkinetic children.
In a double-blind study, 62 hyperkinetic children were randomly assigned to 8 weeks of treatment with either placebo, thioridazine, or d-amphetamine. The overall clinical symptomatology improved with all three substances, although d-amphetamine was significantly superior to placebo and thioridazine. Out of eight symptom clusters rated by the parents, two improved significantly with placebo, one with thioridazine, and six with d-amphetamine. The d-amphetamine was superior to placebo in reducing muscular tension and superior to thioridazine in decreasing hyperactive-impulsive behavior, psychosomatic problems, and muscular tension. Out of four teachers' symptom clusters, inattentive-passive behavior was significantly improved by thioridazine (which was also superior to placebo), while hyperactivity was reduced by d-amphetamine. Quantitative evaluation of visual evoked potentials (VEPs) revealed an increase in latencies and decrease in amplitudes during thioridazine treatment. Paradoxically, d-amphetamine also increased latencies, while tending to augment amplitudes. Regression and correlation analysis of clinical symptomatology with VEP variables showed that the shorter the pretreatment latencies and the higher the amplitudes, the more disturbed was the child. Short latencies and small amplitudes in the pretreatment period were predictors of good therapeutic outcome with subsequent thioridazine treatment, while short latencies and high amplitudes were indicative of such with d-amphetamine treatment. During therapy, the greater the drug-induced augmentation of latencies, the greater the clinical improvement. Finally, VEP differences between therapy-responsive and -resistant patients were explored and discussed.
D000284:Administration, Oral; D000293:Adolescent; D000661:Amphetamine / Q000008:administration & dosage / Q000627:therapeutic use*; D001007:Anxiety; D002648:Child; D002652:Child Behavior; D002986:Clinical Trials as Topic; D005071:Evoked Potentials / Q000187:drug effects*; D006801:Humans; D006948:Hyperkinesis / Q000188:drug therapy* / Q000503:physiopathology; D007175:Impulsive Behavior; D007858:Learning; D008297:Male; D009043:Motor Activity; D009129:Muscle Tonus; D010290:Parents; D010919:Placebos; D011569:Psychiatric Status Rating Scales; D012574:Schools; D011795:Surveys and Questionnaires; D013881:Thioridazine / Q000008:administration & dosage / Q000627:therapeutic use*
D010919:Placebos; D000661:Amphetamine; D013881:Thioridazine